# 2011

Athens, Greece

I-01 Leon AaronsPopulation Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and ChildrenWednesday 10:15-11:45 |

I-02 Mona AlameddinePopulation Pharmacokinetic Analysis and Effects of Raltegravir In HIV positive and Healthy IndividualsWednesday 10:15-11:45 |

I-03 Sarah AlghanemDevelopment of a Tobramycin Dosage Adjustment Nomogram for Patients with Cystic FibrosisWednesday 10:15-11:45 |

I-04 Hesham Al-SallamiA semi-mechanistic model for estimating fat free mass in childrenWednesday 10:15-11:45 |

I-05 Claire AmberyModelling impact of dropout mechanisms in Chronic Obstructive Pulmonary Disease (COPD) Wednesday 10:15-11:45 |

I-06 Orna AmirPredictive Model for Identification of Responders/Non Responders in Metastatic Breast Cancer Patients Treated with Docetaxel Wednesday 10:15-11:45 |

I-07 Anders KristofferssonOptimal design of in vitro time kill curve experiments for the evaluation of antibiotic effects.Wednesday 10:15-11:45 |

I-08 Claus AndersenTrial Sample Size Estimation and Study Design Assessment using Monte Carlo SamplingWednesday 10:15-11:45 |

I-09 Jacqueline Anderson Comparative pharmacokinetics of dimethoate poisoning in the minipig and humanWednesday 10:15-11:45 |

I-10 Christian BartelsPopulation PK Model for Pooled Data of Different Oral Diclofenac FormulationsWednesday 10:15-11:45 |

I-11 Paul BaverelA novel covariate search method intended for PKPD models with nonparametric parameter distributionsWednesday 10:15-11:45 |

I-12 Caroline BazzoliNew features for population design evaluation and optimisation with R functions: PFIM Interface 3.1 and PFIM 3.2Wednesday 10:15-11:45 |

I-13 Benoît BeckFrom the Experimental Model Settings to the Physical System for Interpretable Decision MakingWednesday 10:15-11:45 |

I-14 Francesco BellantiRelevance of QT-RR correlations in the assessment of QTc-interval prolongation in clinical trial simulationsWednesday 10:15-11:45 |

I-15 Brendan BenderA semi-mechanistic population Pharmacokinetic-Pharmacodynamic (PKPD) model of thrombocytopenia characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer Wednesday 10:15-11:45 |

I-16 Julie BertrandExtensive Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian PatientsWednesday 10:15-11:45 |

I-17 Julie BertrandMultiple SNP analysis with HyperLasso in Pharmacogenetic Studies using Nonlinear Mixed Effects ModelsWednesday 10:15-11:45 |

I-18 Bruno BiethUsing a Systems Biology Approach to Explore Clinical Diversity and Investigate Mechanism of Drug Action: Example of the RAAS System in HypertensionWednesday 10:15-11:45 |

I-19 Roberto BizzottoDrug Effects on Sleep Data from a 28-Day Clinical Study in Insomniac Patients: Covariate Analysis Using a Multinomial Mixed-Effect Markov-Chain ModelWednesday 10:15-11:45 |

I-20 Marcus BjörnssonPerformance of non-linear mixed effects models with and without taking informative dropout into accountWednesday 10:15-11:45 |

I-21 Michael BlockMechanistic PBPK/PD modeling for prediction of study outcome of cancer therapies: Translating in-vitro information into valid in-vivo predictionsWednesday 10:15-11:45 |

I-22 Irina BondarevaSequential Interacting Multiple Model (IMM) Bayesian Analysis of Carbamazepine and Valproate Repeated Therapeutic Drug Monitoring (TDM) Data from Epileptic Patients Wednesday 10:15-11:45 |

I-23 Guillaume BonnefoisA nonlinear mixed effect model to study albumin-mediated drug transport into endothelial cells in vitro. Wednesday 10:15-11:45 |

I-24 Stephan BorghorstAge Dependent Volume of Distribution of Pegylated Asparaginase (OncasparTM) in children and adultsWednesday 10:15-11:45 |

I-25 Massoud BoroujerdiA Negative feedback model for a mechanism based description of longitudinal observations: application for bone turnover biomarkers.Wednesday 10:15-11:45 |

I-26 Marion Bouillon-PichaultModeling Pain score in clinical trials using a joint survival-longitudinal mixed model with a Beta distribution in presence of missing values not occurring at random.Wednesday 10:15-11:45 |

I-27 Marion Bouillon-PichaultPharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4Wednesday 10:15-11:45 |

I-28 Christine BrandquistPK/PD Modeling of the Effect of Intravenous Doses of Anzemet® (dolasetron mesylate) and Its Metabolite (hydrodolasetron) on the QT Interval in Healthy Subjects Wednesday 10:15-11:45 |

I-29 Karl BrendelA comparison of MONOLIX, NONMEM 6 and NONMEM 7 based on a simulated PK exampleWednesday 10:15-11:45 |

I-30 Margreke BrillCefazolin pharmacokinetics in morbidly obese patients following a prophylactic dose during weight reducing surgery.Wednesday 10:15-11:45 |

I-31 Anne BrochotSpecifying Models with Time Dependent Pharmacokinetic Parameters in NONMEMWednesday 10:15-11:45 |

I-32 Jacob BrogrenSeparate vs. simultaneous analysis of co-primary endpoints in Alzheimer’s disease clinical trialsWednesday 10:15-11:45 |

I-33 Vincent BuchheitEfficient quality review for modeling input datasetWednesday 10:15-11:45 |

I-34 Núria Buil BrunaThe feasibility of model-based exposure calculations in preclinical toxicologyWednesday 10:15-11:45 |

I-35 Vicente G. CasaboBioequivalence trials simulation to select the best analyte for acetylsalicylic acid Wednesday 10:15-11:45 |

I-36 Massimo CellaImplementation of Pharmacokinetic Bridging for Drug Combinations in ChildrenWednesday 10:15-11:45 |

I-37 Anne ChainCan First-Time-In-Human Trials Replace Thorough QT Studies?Wednesday 10:15-11:45 |

I-38 Pascal ChanuA dose selection rationale based on hemodynamics for sildenafil in pediatric patients with pulmonary arterial hypertension (PAH)Wednesday 10:15-11:45 |

I-39 Georgia CharkoftakiPharmacokinetics of doripenem in cerebrospinal fluidWednesday 10:15-11:45 |

I-41 Marylore ChenelDeveloping an In Vitro – In Vivo Correlation Model Using a Population Approach in NONMEMWednesday 10:15-11:45 |

I-42 Marylore ChenelBSA-adjusted dose? An old method to fight old biasWednesday 10:15-11:45 |

I-43 S. Y. Amy CheungStructural identifiability of parallel pharmacokinetic experiments as constrained systemsWednesday 10:15-11:45 |

I-44 Jason ChittendenEvaluation of the Lindstrom-Bates FOCE Algorithm with Simulated Pharmacokinetic DatasetsWednesday 10:15-11:45 |

I-45 Steve ChoyApplication of an integrated glucose-insulin model to investigate the effects of glibenclamide and its active metabolites on postprandial glucose and insulin concentrations in healthy volunteersWednesday 10:15-11:45 |

I-46 Christine XuPopulation Pharmacokinetics (PPK) and Pharmacokinetic-Pharmacodynamic (PK/PD) of Vicriviroc in Treatment Naive HIV Wednesday 10:15-11:45 |

I-47 Jae Yong ChungModelling of Atorvastatin Pharmacokinetics in relation to SLCO1B1 genotype and Simulations for Bioequivalence Study Wednesday 10:15-11:45 |

I-48 Karina BleiEvaluation of a PBPK Model for Preterm Neonates by Predicting Paracetamol PharmacokineticsWednesday 10:15-11:45 |

I-49 Adriaan CletonPopulation Pharmacokinetics of a Monoclonal Antibody Tanezumab in Chronic Pelvic Pain ConditionsWednesday 10:15-11:45 |

I-50 Emmanuelle CometsSAEMIX, an R version of the SAEM algorithmWednesday 10:15-11:45 |

I-51 Emmanuelle CometsPrediction discrepancies (pd) for evaluation of models with data under limit of quantificationWednesday 10:15-11:45 |

I-52 Emmanuelle CometsA comparison of bootstrap approaches for estimating standard errors of parameters in linear mixed effects modelsWednesday 10:15-11:45 |

I-53 Carolyn CoulterUtilising prior literature population models to inform clinical practice - a dosing regimen for immediate N-acetyl cysteine treatment of paracetamol overdoseWednesday 10:15-11:45 |

I-54 Alexander DanisSet-valued methods for estimation of parameters in population modelsWednesday 10:15-11:45 |

I-55 Roosmarijn De CockMaturation of GFR in preterm and term neonates reflected by clearance of different antibioticsWednesday 10:15-11:45 |

I-56 Elizabeth de LangeMechanism-based PK-PD model of remoxipride with rat-to-human extrapolation: characterizing remoxipride target site PK and systems homeostatic feedback Wednesday 10:15-11:45 |

I-57 Willem de WinterDynamics of a Two-Receptor Binding Model: How Affinities and Capacities Translate into Long- and Short-Term Behaviour and Physiological CorollariesWednesday 10:15-11:45 |

I-58 Maud DelattrePharmacokinetics and stochastic differential equations : model and methodology.Wednesday 10:15-11:45 |

I-59 Ivan DeminLongitudinal model-based meta-analysis in rheumatoid arthritis: an application towards model based drug developmentWednesday 10:15-11:45 |

I-60 Paolo DentiPopulation PK of Isoniazid in South African Adults. Wednesday 10:15-11:45 |

I-61 Vincenzo Luca Di IorioApplication of Stochastic Differential Equations to Disease Progression in a Neuropathic Pain Model in RatsWednesday 10:15-11:45 |

I-62 Kristin DickschenPharmacogenomics of Tamoxifen In Female Patients: A PBPK Model-based Investigation Including The Three Main Metabolites Wednesday 10:15-11:45 |

I-63 Jeroen DiepstratenPharmacodynamics of nadroparin using anti-Xa levels in morbidly obese patients upon subcutaneous administration of 5700 IU Wednesday 10:15-11:45 |

I-64 Aris DokoumetzidisNumerical solution of nonlinear fractional compartmental systemsWednesday 10:15-11:45 |

I-65 Aris DokoumetzidisMultiple dosing for linear fractional pharmacokinetic systemsWednesday 10:15-11:45 |